INT187717

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2005
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 11
Total Number 11
Disease Relevance 2.85
Pain Relevance 0.45

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (CYP19A1) small molecule metabolic process (CYP19A1) endoplasmic reticulum (CYP19A1)
cytoplasm (CYP19A1)
Anatomy Link Frequency
oocyte 2
CYP19A1 (Homo sapiens)
Pain Link Frequency Relevance Heat
endometriosis 56 97.52 Very High Very High Very High
agonist 276 89.44 High High
backache 8 88.72 High High
headache 9 88.12 High High
Bioavailability 8 56.52 Quite High
antagonist 353 53.36 Quite High
corticosteroid 64 18.32 Low Low
dexamethasone 40 5.00 Very Low Very Low Very Low
cva 14 5.00 Very Low Very Low Very Low
cytokine 10 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Reprotox - General 3 304 99.84 Very High Very High Very High
Endometriosis (extended) 123 98.88 Very High Very High Very High
Breast Cancer 119 97.56 Very High Very High Very High
Low Back Pain 8 88.72 High High
Advanced Or Metastatic Breast Cancer 39 88.64 High High
Headache 9 88.12 High High
Cancer 36 87.84 High High
Hot Flashes 8 87.72 High High
Asthenia 8 87.20 High High
Endometriosis 8 79.96 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Studies of aromatase inhibitors in the second-line setting
Regulation (Studies) of Negative_regulation (inhibitors) of aromatase
1) Confidence 0.42 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001219 Disease Relevance 0.15 Pain Relevance 0.04
Moreover, the time of administering an aromatase inhibitor during the latter part of the follicular phase as well as the irreversible nature of aromatase inhibition constitute important differences from our model of using a REVERSIBLE aromatase inhibitor, TEMPORARILY, EARLY in the menstrual cycle that has a SHORT half-life.
Regulation (administering) of Negative_regulation (inhibitor) of aromatase
2) Confidence 0.35 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0 Pain Relevance 0
Hypotheses behind the use of aromatase inhibitors for ovarian stimulation
Regulation (use) of Negative_regulation (inhibitors) of aromatase
3) Confidence 0.35 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0.47 Pain Relevance 0.18
1.4 Concerns regarding the use of aromatase inhibitors in infertility treatment
Regulation (use) of Negative_regulation (inhibitors) of aromatase associated with reprotox - general 3
4) Confidence 0.35 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0.79 Pain Relevance 0.20
Limitations of preliminary data on use of aromatase inhibitors for ovarian stimulation
Regulation (use) of Negative_regulation (inhibitors) of aromatase
5) Confidence 0.35 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0 Pain Relevance 0.03
Future avenues for the use of aromatase inhibitors for infertility management
Regulation (use) of Negative_regulation (inhibitors) of aromatase associated with reprotox - general 3
6) Confidence 0.35 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0.30 Pain Relevance 0
However, we have found these aromatase inhibitors to be effective in inhibiting the aromatase enzyme and effectively decrease estrogen levels in women of the reproductive age group during their successful use for ovarian stimulation [417,418,431,432].
Regulation (effective) of Negative_regulation (inhibiting) of aromatase enzyme
7) Confidence 0.35 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0.10 Pain Relevance 0
Fourth: the absence of significant rise in androgen levels would have prevented any possible unwanted effects on the terminal part of the oocyte maturation and ovulation.


1.4.2 Direct effect of the aromatase inhibitors on the developing oocyte, fertilization and embryogenesis

Regulation (effect) of Negative_regulation (inhibitors) of aromatase in oocyte
8) Confidence 0.35 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0 Pain Relevance 0
However, we have found these aromatase inhibitors to be effective in inhibiting the aromatase enzyme and effectively decrease estrogen levels in women of the reproductive age group during their successful use for ovarian stimulation [417,418,431,432].
Regulation (effective) of Negative_regulation (inhibitors) of aromatase
9) Confidence 0.35 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0.10 Pain Relevance 0
Efficacy of aromatase inhibitors
Regulation (Efficacy) of Negative_regulation (inhibitors) of aromatase
10) Confidence 0.32 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682397 Disease Relevance 0.24 Pain Relevance 0
In the setting of hormone receptor positive breast cancer, mTOR inhibition and the resulting increase in Akt signaling could result in ER phosphorylation on Ser167 and negate the effects of aromatase inhibition, thus limiting the therapeutic benefit of this combination.


Regulation (effects) of Negative_regulation (inhibition) of aromatase associated with breast cancer
11) Confidence 0.18 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2242654 Disease Relevance 0.70 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox